PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-7.32%
Both companies show declining cash positions (-7.32% vs TRVN's -17.75%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-7.32%
Below half of TRVN's -17.75%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-58.49%
Above 1.5x TRVN's -23.50%. Michael Burry might investigate for potential short-term asset misclassification or risk.
-6.31%
Below half of TRVN's -18.28%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-8.93%
≥ 1.5x TRVN's -5.92%. David Dodd sees more aggressive capex. Confirm it's not overspending.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.62%
Higher Other Non-Current Assets Growth compared to TRVN's zero value, indicating worse performance.
-7.75%
0.75-0.9x TRVN's -9.34%. Bill Ackman questions if the competitor invests more robustly in future growth.
No Data
No Data available this quarter, please select a different quarter.
-6.35%
Below half of TRVN's -16.37%. Michael Burry sees a potential red flag for stagnation or capital shortage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
5.18%
Less than half of TRVN's 100.00%. David Dodd sees fewer expansions in other current obligations.
5.07%
Less than half of TRVN's 16.90%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-0.44%
50-75% of TRVN's -0.77%. Bruce Berkowitz notes a smaller yoy liability buildup than competitor.
No Data
No Data available this quarter, please select a different quarter.
0.54%
Less than half of TRVN's 1.42%. David Dodd sees far fewer liability expansions relative to competitor.
No Data
No Data available this quarter, please select a different quarter.
-1.80%
≥ 1.5x TRVN's -0.82%. David Dodd sees higher yoy retained profits than competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-14.26%
0.5-0.75x TRVN's -22.96%. Martin Whitman is wary of lagging equity growth vs. competitor.
-6.35%
Below half TRVN's -16.37%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
-8.07%
Less than half of TRVN's -94.51%. David Dodd sees less overall debt expansion vs. competitor.
7.30%
Less than half of TRVN's -156.99%. David Dodd sees better deleveraging or stronger cash buildup than competitor.